DexCom, Inc. (ETR:DC4)
Germany · Delayed Price · Currency is EUR | Market Cap | 20.12B -17.7% |
| Revenue (ttm) | 4.18B +16.2% |
| Net Income | 806.94M +73.8% |
| EPS | 2.03 +75.5% |
| Shares Out | n/a |
| PE Ratio | 24.94 |
| Forward PE | 23.25 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 205 |
| Average Volume | 373 |
| Open | 51.80 |
| Previous Close | n/a |
| Day's Range | 51.60 - 51.80 |
| 52-Week Range | 47.00 - 77.99 |
| Beta | 1.40 |
| RSI | 44.39 |
| Earnings Date | Apr 30, 2026 |
About DexCom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin;... [Read more]
Financial Performance
In 2025, DexCom's revenue was $4.66 billion, an increase of 15.60% compared to the previous year's $4.03 billion. Earnings were $836.30 million, an increase of 45.14%.
Financial numbers in USD Financial StatementsNews
DexCom initiated with a Buy at Benchmark
Benchmark last night initiated coverage of DexCom (DXCM) with a Buy rating and $77 price target The company is positioned for margin expansion over the next two years as it…
DexCom initiated with a Buy at Benchmark
Benchmark initiated coverage of DexCom (DXCM) with a Buy rating.
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Dexcom to Host Investor Day on May 14, 2026
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on Thursday, May 14, 2026 from 1:15 PM until approximately 3:30 PM PDT (4:15 PM – 6:30 PM EDT)....
DexCom price target lowered to $79 from $84 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on DexCom (DXCM) to $79 from $84 and keeps a Buy rating on the shares.
DexCom price target lowered to $80 from $87 at Baird
Baird lowered the firm’s price target on DexCom (DXCM) to $80 from $87 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results showing…
DexCom price target lowered to $77 from $83 at Bernstein
Bernstein lowered the firm’s price target on DexCom (DXCM) to $77 from $83 and keeps an Outperform rating on the shares. The firm notes sales grew 12% organic to $1.19B…
DexCom price target lowered to $75 from $84 at TD Cowen
TD Cowen lowered the firm’s price target on DexCom (DXCM) to $75 from $84 and keeps a Buy rating on the shares. The firm said the Q1 quarterly report checked…
DexCom price target lowered to $75 from $90 at Mizuho
Mizuho analyst Anthony Petrone lowered the firm’s price target on DexCom (DXCM) to $75 from $90 and keeps an Outperform rating on the shares.
DexCom price target lowered to $81 from $83 at Raymond James
Raymond James lowered the firm’s price target on DexCom (DXCM) to $81 from $83 and keeps a Strong Buy rating on the shares. Despite a high bar, results exceeded expectations…
DexCom price target raised to $100 from $95 at Canaccord
Canaccord raised the firm’s price target on DexCom (DXCM) to $100 from $95 and keeps a Buy rating on the shares. The firm said they reported alighlty better than expected…
DexCom price target lowered to $67 from $72 at Barclays
Barclays lowered the firm’s price target on DexCom (DXCM) to $67 from $72 and keeps an Underweight rating on the shares. The firm remains concerned over rising competition following the…
Dexcom reaffirms full-year forecast after topping quarterly estimates
Medical device maker Dexcom on Thursday reiterated its full-year revenue forecast after beating Wall Street estimates for quarterly results, helped by strong demand for its continuous glucose monitor...
DexCom Earnings Call Transcript: Q1 2026
Q1 2026 delivered 15% revenue growth, record global new patient starts, and margin expansion, driven by strong U.S. and international performance, new product launches, and expanded coverage. Guidance for 2026 was reaffirmed, with raised margin outlook and continued focus on innovation and access.
DexCom affirms FY26 revenue $5.16B-$5.25B, consensus $5.23B
Dexcom (DXCM) is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin: Non-GAAP Gross Profit Margin of approximately 63-64%; Non-GAAP Operating Margin of approxim...
DexCom reports Q1 EPS 56c, consensus 47c
Reports Q1 revenue $1.19B, consensus $1.18B. “Dexcom (DXCM) delivered strong revenue growth and margin performance to start the year, reflecting healthy demand for Dexcom CGM and continued operational...
Dexcom Reports First Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports First Quarter 2026 Financial Results.
DexCom price target lowered to $80 from $85 at BTIG
BTIG lowered the firm’s price target on DexCom (DXCM) to $80 from $85 and keeps a Buy rating on the shares as part of a broader research name on Medical…
Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, April 30, 2026. Management will...
DexCom price target raised to $84 from $77 at Citi
Citi analyst Joanne Wuensch raised the firm’s price target on DexCom (DXCM) to $84 from $77 and keeps a Buy rating on the shares. The firm adjusted targets in the…
Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
BARCELONA, Spain--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for pe...
DexCom Transcript: 47th Annual Raymond James Institutional Investor Conference
Leadership transition and a focus on technology, customer experience, and international growth are driving strategy. 2025 saw strong revenue and user growth, with 2026 guidance pointing to further margin expansion and new product launches, including the G8 sensor.
Dexcom Appoints Rick Osterloh to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Dexcom Appoints Rick Osterloh to Board of Directors.
DexCom management to meet virtually with BTIG
Virtual Meeting to be held on March 5 hosted by BTIG.
HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is invest...